IL6 and COVID-19: Besides, some additional pro thrombotic events observed in COVID-19 patients, including an increase in serum IL-6 that has potentially characterized activities platelets [10] and coagulation factors [11], T lymphocytes [12] as well as IL-6 and TNF-α may play direct roles in promoting micro vascular damage associated with AT-II [13].